Four Hot-selling Specifications of Tirzepatide in the Market in 2023

Four Hot-selling Specifications of Tirzepatide in the Market in 2023 -By Polypeptide.ltd

Authoritative source：PubChem Tirzepatide is administered subcutaneously via an injection. It is not available in oral form at this time. It is available in various specifications: 5mg/vial ； 10mg/vial ； 15mg/vial ； 30mg/vial ； 10vials/box. Standard dosing is once weekly, with the usual initiation dose being 5 mg/0.5 mL.

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

Tirzepatide work for diabetes ①Stimulation of Insulin Release: Tirzepatide activates both the GIP receptor and the GLP-1 receptor, which are found on pancreatic beta cells. When these receptors are activated, they stimulate the release of insulin from the pancreas in response to elevated blood sugar levels. Insulin is a hormone that helps cells take up glucose from the bloodstream, thereby reducing blood sugar levels. ②Inhibition of Glucagon: In addition to stimulating insulin release, tirzepatide also inhibits the release of glucagon. Glucagon is a hormone that raises blood sugar levels by promoting the release of glucose from the liver. By reducing glucagon levels, tirzepatide helps to lower blood sugar.

Tirzepatide work for weight loss ①Slowing Gastric Emptying: Tirzepatide’s activation of the GLP-1 receptor helps to slow down the emptying of the stomach. This results in a delayed release of nutrients into the intestines, leading to a longer-lasting feeling of fullness after eating. As a result, individuals may naturally consume fewer calories during meals. ②Appetite Suppression: GLP-1 receptor agonists like Tirzepatide can suppress appetite signals in the brain This can reduce cravings and the desire to eat between meals, which can contribute to a decrease in overall caloric intake

Tirzepatide cost monthly Prescribed Tirzepatide’s list price is quite high, ranging from around USD 1,100 to USD 1,500 for a month’s supply that lasts four weeks. With tirzepatide can be purchased online, Tirzepatide price seems affordable from online supplier. But please make sure buy it from a reliable supplier.

Reference citations [1] Ahangarpour M, Kavianinia I, Harris PW, Brimble MA (January 2021). "Photo-induced radical thiol-ene chemistry: a versatile toolbox for peptide-based drug design". Chemical Society Reviews.

Royal Society of Chemistry.

50 (2): 898–944. doi:10.1039/d0cs00354a. PMID 33404559. S2CID 230783854.

[2] "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023.

Retrieved 22 January 2023. This article incorporates text from this source, which is in the public

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

domain.

[3] Jump up to:a b c d e f g h i j k l "Drug Trials Snapshots: Mounjaro". U.S. Food and Drug Administration (FDA). 13 June 2023. Retrieved 14 June 2023. This article incorporates text from this source, which is in the public domain.

[4] Dutta D, Surana V, Singla R, Aggarwal S, Sharma M (November–December 2021). "Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis". Indian Journal of Endocrinology and Metabolism. 25 (6): 475–489. doi:10.4103/ijem.ijem_423_21. PMC 8959203. PMID 35355921.

[5] Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. (4 June 2022). "Tirzepatide Once Weekly for the Treatment of Obesity". NEJM. 387 (3): 205–216. doi:10.1056/NEJMoa2206038. PMID 35658024. S2CID 249385412. Archived from the original on 5 June 2022. Retrieved 6 June 2022.

[6] "Lilly : Phase 3 Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes". Business Insider. RTTNews. 19 October 2021. Archived from the original on 28 October 2021. Retrieved 28 October 2021.

[7] Kellaher, Colin (28 April 2022). "Eli Lilly's Tirzepatide Meets Main Endpoints in Phase 3 Obesity Study". MarketWatch. Dow Jones Newswires. Archived from the original on 29 April 2022.

Retrieved 29 April 2022.

[8] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al.

(August 2021). "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes".

The New England Journal of Medicine.

385 (6): 503–515. doi:10.1056/NEJMoa2107519. PMID 34170647. S2CID 235635529.

[9] Dee, Jane E. (6 June 2022). "More Than 20% Weight Reduction in Individuals With Obesity". Yale Department of Internal Medicine. Archived from the original on 10 June 2022.

Retrieved 12 June 2022.

[10] Davis, Nicola (5 June 2022). "Diabetes drug leads to notable weight loss in people with obesity – study". The Guardian. Archived from the original on 11 June 2022. Retrieved 12 June 2022.

[11] World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

[12] Jump up to:a b c "Mounjaro EPAR". European Medicines Agency (EMA). 18 July 2022. Archived from the original on 12 December 2022. Retrieved 2 January 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[13] Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G (November 2022).

"Tirzepatide: A Systematic Update".

Int J Mol Sci. 23 (23). doi:10.3390/ijms232314631. PMC 9741068. PMID 36498958.

[14] "Mounjaro: Pending EC decision". European Medicines Agency. 22 July 2022. Archived from the original on 28 July 2022. Retrieved 30 July 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[15] "Mounjaro Product information". Union Register of medicinal products. Archived from the original on 8 February 2023. Retrieved 3 March 2023.

[16] "Drug and Health Product Submissions Under Review (SUR): New drug submissions completed". Health Canada. 10 March 2021. Archived from the original on 5 January 2023.

Retrieved 5 January 2023.

[17] Jump up to:a b Min T, Bain SC (January 2021). "The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials". Diabetes Therapy. 12 (1): 143–157. doi:10.1007/s13300-020-00981-0. PMC 7843845. PMID 33325008.

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/